Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Kristeleit

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Cell|October 22, 2021
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancerDuncan R McKenzie, Miguel Muñoz-Ruiz, Leticia Monin, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Cancers|January 21, 2022
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer CentreBeth Russell, Charlotte Moss, Eirini Tsotra, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Cell|October 22, 2021
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancerDuncan R McKenzie, Miguel Muñoz-Ruiz, Leticia Monin, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Cancers|January 21, 2022
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer CentreBeth Russell, Charlotte Moss, Eirini Tsotra, et al.
Pageof 2